Information Provided By: 
Fly News Breaks for March 28, 2016
AMGN, REGN
Mar 28, 2016 | 07:32 EDT
Canaccord lowered its price target on Regeneron (REGN) to $450 from $525 citing various uncertainties that it expects will weigh on the shares. The firm included Phase 3 data for Fovista/Lucentis, long-term outcome studies for Repatha, Phase 2 results in ALN-PCSsc, and the outcome of a patent dispute with Amgen (AMGN) for PCSK9. Canaccord maintained its Hold rating on Regeneron shares.
News For REGN;AMGN From the Last 2 Days
There are no results for your query REGN;AMGN
